<DOC>
	<DOCNO>NCT01140841</DOCNO>
	<brief_summary>The purpose clinical trial determine maximum tolerate dose Fipamezole adult patient Parkinson 's disease receiving levodopa .</brief_summary>
	<brief_title>A Study Safety Tolerability Fipamezole Adult Subjects With Parkinson 's Disease Who Are Receiving Levodopa</brief_title>
	<detailed_description>Parkinson 's Disease second common neurodegenerative disorder worldwide . While treatment dopaminergic agent like levodopa , mainstay treatment , effective early phase disease , benefit decrease disease progression , problem dyskinesia on-off phenomenon begin manifest . In study , fipamezole , new antagonist adrenergic receptor , investigate well understand safety side-effect profile patient Parkinson 's Disease . The sample method use simple random sampling .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Subject man woman 30 75 year age , inclusive , intact oral mucosa Screening ( Visit 1 ) Randomization ( Visit 2 ) . 2 . Subject diagnosis idiopathic Parkinson 's disease define accord UK Parkinson 's Disease Society Brain Bank Clinical Diagnosis criterion . 3 . Subject receive stable regimen least three daily administration levodopa ( peripheral dopa decarboxylase inhibitor ) , dose change least 4 week prior Randomization ( Visit 2 ) . 4 . Subject rat stage 2 4 Hoehn Yahr scale . 5 . If currently take medication ( levodopa ) , subject must stable regimen , define dose change least 1 month prior Randomization ( Visit 2 ) . 6 . Subject demonstrate ability comprehend study procedure provide inform consent . 7 . Female subject must either postmenopausal least 1 year surgically sterilize least 3 month prior Randomization ( Visit 2 ) . Male subject must either sterile willing use 2 approve method contraception engage sexual intercourse female partner Randomization ( Visit 2 ) 30 day last dose study drug . 8 . Subject upper arm circumference le 24 cm 42 cm arm . 1 . Subject participate investigational medication study within 3 month prior Randomization ( Visit 2 ) . 2 . Subject immediate family member site Investigators sponsor employee . 3 . Subject history presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic condition , opinion Investigator , would jeopardize safety subject validity study result . 4 . Subject impaired renal function ( defined creatinine level ≥ 1.5 time upper limit normal ) Screening ( Visit 1 ) . 5 . Subject impaired hepatic function ( define SGOT/AST SGPT/ALT level ≥ 1.5 time upper limit normal ) Screening ( Visit 1 ) . 6 . Subject second thirddegree atrioventricular block sick sinus syndrome , atrial fibrillation , atrial flutter , severe unstable angina , congestive heart failure , myocardial infarction within 3 month screen visit significant ECG abnormality , include QRS &gt; 110 msec , PR interval &gt; 230 msec , QTc ≥ 450 msec male subject , QTc ≥ 470 msec female subject . 7 . Subject history risk factor Torsades de Pointes , include unexplained syncope , know long QT syndrome , clinically significant abnormal laboratory assessment hypokalemia , hypercalcemia , hypomagnesemia . Subjects family history long QT syndrome Brugada syndrome also exclude . 8 . Subject immediate risk require hospitalization . 9 . Subject significant tremor dyskinesia , opinion Investigator , might interfere reliable assessment continuous Holter ECG ABPM . 10 . Subject , opinion Investigator , clinically important abnormality his/her physical examination , electrocardiography , vital sign measurement , laboratory assessment . 11 . Subject treat disallowed medication discontinue prior Randomization ( Visit 2 ) ( See Table 6 ) . 12 . Subject current diagnosis substance abuse history alcohol drug abuse past 2 year prior Screening ( Visit 1 ) . 13 . Subject positive finding urine drug screen Screening ( Visit 1 ) . 14 . Subject allergy fipamezole excipients .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Dyskinesia</keyword>
</DOC>